Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease

Area of Science:

• Neuroscience
• Biochemistry
• Genetics

Background:

• Mitochondrial dysfunction is a key pathological mechanism in Parkinson's Disease (PD).
• This dysfunction leads to oxidative stress, DNA damage, and neuronal death.
• Evidence comes from human studies and animal models of neurodegeneration.

Purpose of the Study:

• To review therapeutic approaches targeting mitochondrial dysfunction in Parkinson's Disease.
• To highlight agents currently in clinical trials and preclinical development.
• To explore novel therapeutic targets for PD treatment.

Main Methods:

• Review of existing scientific literature and clinical trial data.
• Analysis of preclinical studies in animal models of neurodegeneration.
• Identification of key molecular pathways and therapeutic targets.

Main Results:

• Creatine and Coenzyme Q10 (CoQ10) are in Phase III clinical trials for PD.
• Mitochondrial-targeted antioxidants and SS peptides show efficacy in preclinical models.
• Nrf2/ARE pathway activators (e.g., sulforaphane, curcumin) demonstrate neuroprotective effects.

Conclusions:

• Targeting mitochondrial dysfunction and oxidative stress offers significant therapeutic potential for PD.
• Emerging targets like PGC-1alpha and sirtuins present future avenues for PD treatment development.
• Activating endogenous antioxidant defenses via pathways like Nrf2/ARE is a promising strategy.